X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs STERLING BIOTECH - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA STERLING BIOTECH GLENMARK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 12.7 -0.4 - View Chart
P/BV x 2.3 0.0 15,969.0% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
STERLING BIOTECH
Dec-13
GLENMARK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs93011 8,857.1%   
Low Rs5173 15,217.6%   
Sales per share (Unadj.) Rs322.626.8 1,203.5%  
Earnings per share (Unadj.) Rs28.5-15.0 -190.5%  
Cash flow per share (Unadj.) Rs39.2-5.5 -717.4%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.054.9 333.4%  
Shares outstanding (eoy) m282.17267.87 105.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 865.2%   
Avg P/E ratio x25.4-0.5 -5,466.9%  
P/CF ratio (eoy) x18.5-1.3 -1,451.6%  
Price / Book Value ratio x4.00.1 3,123.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,862 10,968.8%   
No. of employees `00013.71.4 1,013.0%   
Total wages/salary Rs m18,718547 3,423.3%   
Avg. sales/employee Rs Th6,636.85,303.3 125.1%   
Avg. wages/employee Rs Th1,364.7403.8 337.9%   
Avg. net profit/employee Rs Th586.1-2,959.0 -19.8%   
INCOME DATA
Net Sales Rs m91,0317,181 1,267.7%  
Other income Rs m91443 2,145.5%   
Total revenues Rs m91,9457,223 1,272.9%   
Gross profit Rs m16,154947 1,706.0%  
Depreciation Rs m3,0192,543 118.7%   
Interest Rs m2,8564,377 65.2%   
Profit before tax Rs m11,193-5,931 -188.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-1,924 -163.9%   
Profit after tax Rs m8,039-4,007 -200.6%  
Gross profit margin %17.713.2 134.6%  
Effective tax rate %28.232.4 86.9%   
Net profit margin %8.8-55.8 -15.8%  
BALANCE SHEET DATA
Current assets Rs m69,88714,335 487.5%   
Current liabilities Rs m32,87949,809 66.0%   
Net working cap to sales %40.7-494.0 -8.2%  
Current ratio x2.10.3 738.6%  
Inventory Days Days81403 20.2%  
Debtors Days Days93171 54.8%  
Net fixed assets Rs m28,89255,432 52.1%   
Share capital Rs m282268 105.3%   
"Free" reserves Rs m51,35313,935 368.5%   
Net worth Rs m51,63514,701 351.2%   
Long term debt Rs m41,4189,478 437.0%   
Total assets Rs m125,95473,988 170.2%  
Interest coverage x4.9-0.4 -1,386.0%   
Debt to equity ratio x0.80.6 124.4%  
Sales to assets ratio x0.70.1 744.7%   
Return on assets %8.60.5 1,726.8%  
Return on equity %15.6-27.3 -57.1%  
Return on capital %15.1-6.4 -235.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m36,3171,860 1,952.7%   
Fx outflow Rs m9,72025 39,050.2%   
Net fx Rs m26,5981,835 1,449.5%   
CASH FLOW
From Operations Rs m16,4811,719 958.9%  
From Investments Rs m-10,133-3,148 321.9%  
From Financial Activity Rs m-4,6851,426 -328.5%  
Net Cashflow Rs m1,770-3 -52,058.8%  

Share Holding

Indian Promoters % 48.3 33.9 142.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.0 -  
FIIs % 34.4 9.9 347.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   56,727 21,482 264.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS